Plasma Interleukin-6 and Fatigue in Terminally Ill Cancer Patients

Masatoshi Inagaki, Masako Isono, Toru Okuyama, Yuriko Sugawara, Tatsuo Akechi, Nobuya Akizuki, Maiko Fujimori, Motoko Mizuno, Yasuo Shima, Hiroya Kinoshita, Yosuke Uchitomi

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Fatigue is one of the most distressing symptoms among terminally ill cancer patients. However, no effective intervention has been established. Several studies have suggested the role of cytokines in fatigue in cancer patients receiving anti-cancer treatment, patients with metastatic cancer, and cancer survivors, but not in terminally ill cancer patients. In the present study, the potential association between fatigue and plasma interleukin-6 (IL-6) was examined in 46 terminally ill cancer patients (median survival: 64.5 days) who received neither steroids nor nonsteroidal anti-inflammatory drugs. Fatigue was evaluated by the Cancer Fatigue Scale (CFS), which consists of multiple dimensions of fatigue, such as Physical, Affective, and Cognitive subscales. Plasma IL-6 levels were measured using an enzyme-linked immunosorbent assay and were compared between patients with and without "clinical fatigue" as defined by the total score of the CFS. Additionally, associations between each of the CFS scores and IL-6 levels were examined. As a result, the IL-6 level in patients with clinical fatigue (n = 27 [59%]; mean, SD, median, and range: 37.1, 46.4, 17.1, and 3.7-182.5 pg/ml, respectively) was significantly higher than those without clinical fatigue (n = 19 [41%]; mean, SD, median, range: 14.3, 12.2, 8.0, and 2.8-45.0 pg/ml, respectively) (P = 0.02). The IL-6 level significantly correlated with the Physical subscale score (r = 0.35, P = 0.02), but not with other subscale scores. In conclusion, IL-6 may play a role in fatigue, especially in the physical dimension, in terminally ill cancer patients. The results of the present study provide information to develop a new treatment strategy for cancer fatigue in terminally ill cancer patients.

Original languageEnglish
Pages (from-to)153-161
Number of pages9
JournalJournal of Pain and Symptom Management
Volume35
Issue number2
DOIs
Publication statusPublished - Feb 2008
Externally publishedYes

Fingerprint

Terminally Ill
Fatigue
Interleukin-6
Neoplasms
Survivors

Keywords

  • cancer
  • Fatigue
  • interleukin-6
  • terminally ill

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology
  • Neurology
  • Nursing(all)

Cite this

Inagaki, M., Isono, M., Okuyama, T., Sugawara, Y., Akechi, T., Akizuki, N., ... Uchitomi, Y. (2008). Plasma Interleukin-6 and Fatigue in Terminally Ill Cancer Patients. Journal of Pain and Symptom Management, 35(2), 153-161. https://doi.org/10.1016/j.jpainsymman.2007.03.009

Plasma Interleukin-6 and Fatigue in Terminally Ill Cancer Patients. / Inagaki, Masatoshi; Isono, Masako; Okuyama, Toru; Sugawara, Yuriko; Akechi, Tatsuo; Akizuki, Nobuya; Fujimori, Maiko; Mizuno, Motoko; Shima, Yasuo; Kinoshita, Hiroya; Uchitomi, Yosuke.

In: Journal of Pain and Symptom Management, Vol. 35, No. 2, 02.2008, p. 153-161.

Research output: Contribution to journalArticle

Inagaki, M, Isono, M, Okuyama, T, Sugawara, Y, Akechi, T, Akizuki, N, Fujimori, M, Mizuno, M, Shima, Y, Kinoshita, H & Uchitomi, Y 2008, 'Plasma Interleukin-6 and Fatigue in Terminally Ill Cancer Patients', Journal of Pain and Symptom Management, vol. 35, no. 2, pp. 153-161. https://doi.org/10.1016/j.jpainsymman.2007.03.009
Inagaki, Masatoshi ; Isono, Masako ; Okuyama, Toru ; Sugawara, Yuriko ; Akechi, Tatsuo ; Akizuki, Nobuya ; Fujimori, Maiko ; Mizuno, Motoko ; Shima, Yasuo ; Kinoshita, Hiroya ; Uchitomi, Yosuke. / Plasma Interleukin-6 and Fatigue in Terminally Ill Cancer Patients. In: Journal of Pain and Symptom Management. 2008 ; Vol. 35, No. 2. pp. 153-161.
@article{90076a1c95434120b452bac0b5edc173,
title = "Plasma Interleukin-6 and Fatigue in Terminally Ill Cancer Patients",
abstract = "Fatigue is one of the most distressing symptoms among terminally ill cancer patients. However, no effective intervention has been established. Several studies have suggested the role of cytokines in fatigue in cancer patients receiving anti-cancer treatment, patients with metastatic cancer, and cancer survivors, but not in terminally ill cancer patients. In the present study, the potential association between fatigue and plasma interleukin-6 (IL-6) was examined in 46 terminally ill cancer patients (median survival: 64.5 days) who received neither steroids nor nonsteroidal anti-inflammatory drugs. Fatigue was evaluated by the Cancer Fatigue Scale (CFS), which consists of multiple dimensions of fatigue, such as Physical, Affective, and Cognitive subscales. Plasma IL-6 levels were measured using an enzyme-linked immunosorbent assay and were compared between patients with and without {"}clinical fatigue{"} as defined by the total score of the CFS. Additionally, associations between each of the CFS scores and IL-6 levels were examined. As a result, the IL-6 level in patients with clinical fatigue (n = 27 [59{\%}]; mean, SD, median, and range: 37.1, 46.4, 17.1, and 3.7-182.5 pg/ml, respectively) was significantly higher than those without clinical fatigue (n = 19 [41{\%}]; mean, SD, median, range: 14.3, 12.2, 8.0, and 2.8-45.0 pg/ml, respectively) (P = 0.02). The IL-6 level significantly correlated with the Physical subscale score (r = 0.35, P = 0.02), but not with other subscale scores. In conclusion, IL-6 may play a role in fatigue, especially in the physical dimension, in terminally ill cancer patients. The results of the present study provide information to develop a new treatment strategy for cancer fatigue in terminally ill cancer patients.",
keywords = "cancer, Fatigue, interleukin-6, terminally ill",
author = "Masatoshi Inagaki and Masako Isono and Toru Okuyama and Yuriko Sugawara and Tatsuo Akechi and Nobuya Akizuki and Maiko Fujimori and Motoko Mizuno and Yasuo Shima and Hiroya Kinoshita and Yosuke Uchitomi",
year = "2008",
month = "2",
doi = "10.1016/j.jpainsymman.2007.03.009",
language = "English",
volume = "35",
pages = "153--161",
journal = "Journal of Pain and Symptom Management",
issn = "0885-3924",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Plasma Interleukin-6 and Fatigue in Terminally Ill Cancer Patients

AU - Inagaki, Masatoshi

AU - Isono, Masako

AU - Okuyama, Toru

AU - Sugawara, Yuriko

AU - Akechi, Tatsuo

AU - Akizuki, Nobuya

AU - Fujimori, Maiko

AU - Mizuno, Motoko

AU - Shima, Yasuo

AU - Kinoshita, Hiroya

AU - Uchitomi, Yosuke

PY - 2008/2

Y1 - 2008/2

N2 - Fatigue is one of the most distressing symptoms among terminally ill cancer patients. However, no effective intervention has been established. Several studies have suggested the role of cytokines in fatigue in cancer patients receiving anti-cancer treatment, patients with metastatic cancer, and cancer survivors, but not in terminally ill cancer patients. In the present study, the potential association between fatigue and plasma interleukin-6 (IL-6) was examined in 46 terminally ill cancer patients (median survival: 64.5 days) who received neither steroids nor nonsteroidal anti-inflammatory drugs. Fatigue was evaluated by the Cancer Fatigue Scale (CFS), which consists of multiple dimensions of fatigue, such as Physical, Affective, and Cognitive subscales. Plasma IL-6 levels were measured using an enzyme-linked immunosorbent assay and were compared between patients with and without "clinical fatigue" as defined by the total score of the CFS. Additionally, associations between each of the CFS scores and IL-6 levels were examined. As a result, the IL-6 level in patients with clinical fatigue (n = 27 [59%]; mean, SD, median, and range: 37.1, 46.4, 17.1, and 3.7-182.5 pg/ml, respectively) was significantly higher than those without clinical fatigue (n = 19 [41%]; mean, SD, median, range: 14.3, 12.2, 8.0, and 2.8-45.0 pg/ml, respectively) (P = 0.02). The IL-6 level significantly correlated with the Physical subscale score (r = 0.35, P = 0.02), but not with other subscale scores. In conclusion, IL-6 may play a role in fatigue, especially in the physical dimension, in terminally ill cancer patients. The results of the present study provide information to develop a new treatment strategy for cancer fatigue in terminally ill cancer patients.

AB - Fatigue is one of the most distressing symptoms among terminally ill cancer patients. However, no effective intervention has been established. Several studies have suggested the role of cytokines in fatigue in cancer patients receiving anti-cancer treatment, patients with metastatic cancer, and cancer survivors, but not in terminally ill cancer patients. In the present study, the potential association between fatigue and plasma interleukin-6 (IL-6) was examined in 46 terminally ill cancer patients (median survival: 64.5 days) who received neither steroids nor nonsteroidal anti-inflammatory drugs. Fatigue was evaluated by the Cancer Fatigue Scale (CFS), which consists of multiple dimensions of fatigue, such as Physical, Affective, and Cognitive subscales. Plasma IL-6 levels were measured using an enzyme-linked immunosorbent assay and were compared between patients with and without "clinical fatigue" as defined by the total score of the CFS. Additionally, associations between each of the CFS scores and IL-6 levels were examined. As a result, the IL-6 level in patients with clinical fatigue (n = 27 [59%]; mean, SD, median, and range: 37.1, 46.4, 17.1, and 3.7-182.5 pg/ml, respectively) was significantly higher than those without clinical fatigue (n = 19 [41%]; mean, SD, median, range: 14.3, 12.2, 8.0, and 2.8-45.0 pg/ml, respectively) (P = 0.02). The IL-6 level significantly correlated with the Physical subscale score (r = 0.35, P = 0.02), but not with other subscale scores. In conclusion, IL-6 may play a role in fatigue, especially in the physical dimension, in terminally ill cancer patients. The results of the present study provide information to develop a new treatment strategy for cancer fatigue in terminally ill cancer patients.

KW - cancer

KW - Fatigue

KW - interleukin-6

KW - terminally ill

UR - http://www.scopus.com/inward/record.url?scp=38349156738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349156738&partnerID=8YFLogxK

U2 - 10.1016/j.jpainsymman.2007.03.009

DO - 10.1016/j.jpainsymman.2007.03.009

M3 - Article

VL - 35

SP - 153

EP - 161

JO - Journal of Pain and Symptom Management

JF - Journal of Pain and Symptom Management

SN - 0885-3924

IS - 2

ER -